Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: Clinical implications of the effect of covariates

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 2, 2014, Pages 399-410

  Lu, Dan ^a   Girish, Sandhya ^a   Gao, Yuying ^b   Wang, Bei ^a   Yi, Joo Hee ^a   Guardino, Ellie ^a   Samant, Meghna ^a   Cobleigh, Melody ^c   Rimawi, Mothaffar ^d   Conte, Pierfranco ^e   Jin, Jin Yan ^a  

^a GENENTECH INC   (United States)

^b Quantitative Solutions   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

Ado trastuzumab emtansine; HER2; Metastatic breast cancer; Pharmacokinetics; T DM1

Indexed keywords

TRASTUZUMAB EMTANSINE;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST METASTASIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; ELIMINATION HALF-LIFE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE; VOLUME OF DISTRIBUTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; MAYTANSINE; PROGNOSIS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; UNITED STATES;

EID: 84907598646     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2500-2     Document Type: Article

References (41)

1. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290
2. Junttila T, Li G, Parsons K, Phillips GL, Sliwkowski MX (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347-356
3. Barok M, Tanner M, Köninki K, Isola J (2011) Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 306:171-179
4. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA (2013) Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31:1157-1163. Erratum in J Clin Oncol 2013;31:2977
5. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791. Erratum in N Engl J Med 2013;368:2442
6. Genentech, Inc (2013) KADCYLA® (ado-trastuzumab emtansine) prescribing information http://www.gene.com/download/pdf/kadcyla-prescribing. pdf. Accessed 20 Sept 2013
7. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris HA 3rd, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69:1229-1240
8. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704
9. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA (2011) Phase II study of the antibody drug conjugate trastu-zumab- DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2- directed therapy. J Clin Oncol 29:398-405
10. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30:3234-3241
11. Wang B, Bianchi GV, Hurvitz SA, Kocsis J, Saad O, Yi J-H, Gupta M, Guardino E, Song C, Girish S (2012) Pharmacokinetics and exposure-efficacy relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer who have not received prior chemotherapy for metastatic disease. Clin Pharm Ther 91(suppl 1):S96. Abstract PIII-1
12. Wang B, Jin J, Wada R, Fang L, Saad O, Olsen S, Althaus B, Swain S, Untch M, Girish S (2012) Pharmacokinetics and expo-sure- efficacy relationship of trastuzumab emtansine in EMILIA, a phase 3 study of trastuzumab emtansine vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer. Cancer Res 72(suppl):469 s. Abstract P5-18-11
13. Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, Holden SN, Modi S (2012) A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118:5733-5740
14. Gupta M, LoRusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, Joshi A, Girish S (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52:691-703
15. Gupta M, Wang B, Carrothers TJ, LoRusso PM, Chu Y-W, Shih T, Loecke D, Joshi A, Saad O, Yi J-H, Girish S (2013) Effects of trastuzumab emtansine (T-DM1) on QT interval and safety of pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Pharmacol Drug Devel 2:11-24
16. Dere R, Yi JH, Lei C, Saad OM, Huang C, Li Y, Baudys J, Kaur S (2013) PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine. Bioanalysis 5:1025-1040
17. Holford N (2005) The visual predictive check-superiority to standard diagnostic (Rorschach) plots. Abstracts of the annual meeting of the population approach group in Europe. 2005:14. Abstract 738. http://www.page-meeting.org/? abstract=738. Accessed 20 Sept 2013
18. Harling K, Uekcert S, Hooker A (2013) NPC/VPC user guide and technical description 2013-05-28 PsN 3.6.2. http://psn.sourceforge.net/pdfdocs/npc-vpc- userguide.pdf. Accessed 23 May 2013
19. Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486-495
20. Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. APS J 11:558-569
21. US Food and Drug Administration (1999) Guidance for industry: population pharmacokinetics. US Food and Drug Administration, Rockville. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/ UCM133184.pdf. Accessed 20 Sept 2013
22. Ralph LD, Sandstrom M, Twelves C, Dobbs NA, Thomson AH (2006) Assessment of the validity of a population pharmacokinetic model for epirubicin. Br J Clin Pharmacol 62:47-55 (Pubitemid 44195242)
23. Han K, Bies R, Johnson H, Capitano B, Venkataramanan R (2011) Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients. Clin Pharmacokinet 50:201-214
24. Gault MH, Longerich L, Harnett JD, Wesolowski C (1992) Predicting glomerular function from adjusted serum creatinine. Nephron 62:249-256
25. US Food and Drug Administration (2010) Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. US Food and Drug Administration, Rockville. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf. Accessed 20 Sept 2013
26. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369 (Pubitemid 41095399)
27. Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659
28. Kuester K, Kloft C (2006) Pharmacokinetics of monoclonal antibodies. In: Meibohm B (ed) Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development, 6th ed. Wiley-VCH Verlag/GmbH & Co. KGaA, Weinheim/Germany, pp 45-92
29. Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, Girish S (2013) An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet 52:657-672
30. US Food and Drug Administration (2011) Clinical pharmacology and biopharmaceuticals review: Adventis http://www.accessdata.fda.gov/drugsatfda- docs/nda/2011/125388Orig1s000ClinPharmR.pdf. Accessed 3 Apr 2014
31. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, DeAngelo DJ, Giles FJ, Marie JP (2012) Phase I studies of AVE9633, an anti- CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 30:1121-1131
32. Prabhu S, Boswell CA, Leipold D, Khawli LA, Li D, Lu D, Theil FP, Joshi A, Lum BL (2011) Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology. Ther Deliv 2:769-791
33. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI (2012) Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 30:2776-2782
34. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821
35. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28:2085-2093
36. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH (2013) Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 31:573-583
37. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS (2001) Pharmacokinetics of gemtuzumab ozogamicin, an antibodytargeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41:1206-1214 (Pubitemid 32983219)
38. Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, Zhang Y, Joshi A, Dresser MJ (2012) A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 51:119-135
39. Wang B, Jin J, Wada R, Fang L, Lu D, Guardino E, Swain SM, Untch M, Girish S (2013) Exposure-efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase 3 study of T-DM1 vs capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC). J Clin Oncol 31(15 s). Abstract 644
40. Jin J, Wang B, Gao Y, Samant M, Li C, Song C, Swain SM, Untch M, Girish S (2013) Exposure-safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC). J Clin Oncol 31(15 s). Abstract 646
41. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu YW, LoRusso PM, Girish S (2012) Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 13:901-910